Clene to file accelerated approval NDA for ALS drug in Q3 2026 after FDA confirms data package

Filed May 4, 2026 · Period ending May 4, 2026 · ~1 min read

Key Changes

• high

  FDA confirmed in writing that Clene's data may support accelerated approval NDA submission for CNM-Au8 ALS treatment, validating the company's faster-to-market regulatory strategy.

  Item 7.01 verify on EDGAR →
• high

  Company plans Q3 2026 NDA submission using neurofilament light (NfL) biomarker as surrogate endpoint, which FDA stated could support accelerated approval without lengthy full clinical benefit trials.

  Item 7.01 verify on EDGAR →
• medium

  NDA will include Phase 2 data from multiple trials showing NfL reductions linked to longer survival, strengthening the application with evidence across different patient populations.

  Item 7.01 verify on EDGAR →